Identifying factors that predict progression in motor neuron disease

Study of Predictive Factors of Progression of Motor Neurone Disease Prognosis and Endophenotype Biomarkers French Database Set up

Observational University Hospital, Lille · NCT02360891

This study is trying to find out what signs can help predict how fast ALS will progress and how long patients can live without serious health issues.

Quick facts

Study typeObservational
Enrollment1000 (estimated)
Ages18 Years to 85 Years
SexAll
SponsorUniversity Hospital, Lille Academic / other
Locations13 sites (Angers and 12 other locations)
Trial IDNCT02360891 on ClinicalTrials.gov

What this trial studies

This observational study aims to analyze a cohort of 1000 patients with Amyotrophic Lateral Sclerosis (ALS), alongside neurological and healthy controls, to identify clinical, biological, imaging, and electrophysiological biomarkers that can predict disease progression and survival without severe comorbidities. The study will utilize a range of assessments including medical history, genetic analyses, and various imaging techniques to establish prognostic markers and differentiate between disease endophenotypes. By employing a large sample size, the study seeks to enhance the statistical power of its findings and improve patient stratification for future clinical trials.

Who should consider this trial

Good fit: Ideal candidates include adults over 18 years with suspected Amyotrophic Lateral Sclerosis or those with other neurodegenerative diseases for control comparisons.

Not a fit: Patients under 18 years or those unable to provide informed consent will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to better prognostic tools for ALS, enabling more personalized treatment approaches and improved outcomes for patients.

How similar studies have performed: While there have been numerous studies on ALS, this approach focusing on multimodal biomarkers and large cohort analysis is relatively novel and has not been extensively tested.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria for ALS patients:

* Patients with suspicion of Amyotrophic lateral sclerosis
* Since the first signs (cramps fasciculation) or first deficit at the diagnosis work up
* Patient older than 18 years
* Patient able to provide informed consent

Inclusion Criteria for healthy controls:

* Subjects older than 18 years (matched population for age and sex with ALS)
* Neurological testing and examination showing no neurological disorders.
* Not having severe disease or life- functional prognosis

Inclusion Criteria for neurological controls:

* Patients having a typical neurodegenerative diseases other than ALS (Parkinson's disease, Alzheimer's disease)
* Not having severe disease or life- functional prognosis
* Patient older than 18 years (matched population for age and sex with ALS)
* Patient able to provide informed consent

Exclusion Criteria:

* Subjects younger than 18 years
* Patient unable to provide informed consent
* Having severe disease or life- functional prognosis
* Contraindications MRI

Where this trial is running

Angers and 12 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Amyotrophic Lateral SclerosisMotor Neuron Diseasemultimodal biomarkersprognosisendophenotypes
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.